| __timestamp | HUTCHMED (China) Limited | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 4326000 |
| Thursday, January 1, 2015 | 29829000 | 226206000 |
| Friday, January 1, 2016 | 39578000 | 94391000 |
| Sunday, January 1, 2017 | 43277000 | 53821000 |
| Monday, January 1, 2018 | 48645000 | 35463000 |
| Tuesday, January 1, 2019 | 52934000 | 46456000 |
| Wednesday, January 1, 2020 | 61349000 | 71318000 |
| Friday, January 1, 2021 | 127125000 | 135256000 |
| Saturday, January 1, 2022 | 136106000 | 102708000 |
| Sunday, January 1, 2023 | 133175999 | 129620000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, HUTCHMED (China) Limited and ImmunityBio, Inc. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, HUTCHMED's SG&A expenses surged by approximately 400%, peaking in 2022. This growth reflects their aggressive expansion and investment in global markets. In contrast, ImmunityBio's expenses fluctuated, with a notable spike in 2015, where expenses increased by over 500% compared to the previous year. By 2023, both companies showed a convergence in their SG&A spending, indicating a potential alignment in strategic priorities. These trends offer a window into the operational focus and market positioning of these pharmaceutical giants, providing valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and HUTCHMED (China) Limited
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
United Therapeutics Corporation or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Insmed Incorporated vs HUTCHMED (China) Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.